For informational purposes only — not investment advice

← Back to signals

MCHP

LONGINSIDER SELLCONGRESS BUY

MICROCHIP TECHNOLOGY INC.

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.

Funds
4
Score
3.39
vs SPY
-34.6%
Stock return (since Q-end)
-35.3%
SPY return (since Q-end)
-0.7%
Current price
$58.64
Days to cover (short int.)
3.8d↓-15.3%
as of 2026-09-30 · shares short vs 2026-06-30

News Summary

Neutral

Microchip delivered strong operational execution through mid-2026 with consecutive earnings beats, robust 35–42% YoY revenue growth driven by industrial and data center demand, and strategic acquisitions of Hailo and Vorago to strengthen AI and radiation-hardened capabilities. However, AI-driven supply-chain constraints in Q2 2027 (revealed November 2026) compressed near-term shipment capacity and triggered significant analyst price-target cuts across major houses, signaling investor concern about demand sustainability and near-term supply dynamics despite maintained positive fundamentals.

Red flags

  • •AI-driven supply shortage limiting factory capacity and pushing lead times to 6–32 weeks, reducing near-term shipment upside
  • •Wave of analyst price-target cuts in November 2026 (Truist $90→$62, Raymond James $125→$80, Citi $95→$75, JPMorgan $120→$100) despite beats, indicating diminished growth confidence
  • •~$53M of non-repeating revenue items in Q2 2027 inflating comparisons; December quarter guidance implies sequential decline despite favorable YoY growth

Funds Buying (4)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Glenview CapitalLarry Robbins266K+266K$24M0.5%—NEW
Soros Fund ManagementSoros Family Office228K+228K$21M0.3%—NEW
Point72Steve Cohen145K+145K$11M<0.1%—NEW
Maverick CapitalLee Ainslie7K+7K$1M<0.1%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where MCHP ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Glenview Capital

position #35 of this fund's book

  1. 32BAUSCH PLUS LOMB CORP$32M
  2. 33BAKER HUGHES COMPANY$27M
  3. 34ELEVANCE HEALTH INC FORMERLY$26M
  4. 35MICROCHIP TECHNOLOGY INC.$24M
  5. 36BRUKER CORP$15M
  6. 37NOVARTIS AG$14M
  7. 38DIGITALOCEAN HLDGS INC$13M

Values are quarter-end position sizes. Shown only for funds where MCHP ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Bjornholt James EricSENIOR CORPORATE VP AND CFOSELL4K$75.32$0.31M2026-08-25↗
Bjornholt James EricSENIOR CORPORATE VP AND CFOSELL837$80.26$0.07M2026-08-17↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
BlackRock, Inc.SC 13G/A63.3M11.6%2026-10-27↗
Vanguard Capital ManagementSC 13G40.6M7.5%2026-04-30↗
Vanguard Portfolio ManagementSC 13G32.5M6.0%2026-04-29↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.

Congressional Trading

MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Gilbert CisneroshouseCA31BUY$1,001 - $15,0002026-06-302026-07-02↗
Earlier trades (1) — dated outside this quarter's window, not counted in the badges
MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Alan Armstrongsenate—BUY$1,001 - $15,0002026-03-272026-07-21↗

Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Apr 1, 2026.